Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Dec 22, 2023
- Accession no.
- 0001447362-23-000190
- Filed
- Dec 22, 2023
- Trade date
- Dec 20-21, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 14 non-derivative transactions. Open-market sales total $393.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2023 | Common Stock | SSaleDisposed | −5,201 | $21.05F2 | −$109,481.05 | 97,517 | Direct | |
| Dec 20, 2023 | Common Stock | SSaleDisposed | −212 | $21.05F2 | −$4,462.6 | 93,447 | Indirect | |
| Dec 20, 2023 | Common Stock | SSaleDisposed | −212 | $21.05F2 | −$4,462.6 | 82,342 | Indirect | |
| Dec 20, 2023 | Common Stock | SSaleDisposed | −77 | $21.05F2 | −$1,620.85 | 12,134 | Indirect | |
| Dec 20, 2023 | Common Stock | SSaleDisposed | −77 | $21.05F2 | −$1,620.85 | 12,131 | Indirect | |
| Dec 20, 2023 | Common Stock | SSaleDisposed | −78 | $21.05F2 | −$1,641.9 | 12,130 | Indirect | |
| Dec 20, 2023 | Common Stock | SSaleDisposed | −77 | $21.05F2 | −$1,620.85 | 12,125 | Indirect | |
| Dec 21, 2023 | Common Stock | SSaleDisposed | −10,999 | $21.40F9 | −$235,378.6 | 86,518 | Direct | |
| Dec 21, 2023 | Common Stock | SSaleDisposed | −448 | $21.40F9 | −$9,587.2 | 92,999 | Indirect | |
| Dec 21, 2023 | Common Stock | SSaleDisposed | −448 | $21.40F9 | −$9,587.2 | 81,894 | Indirect | |
| Dec 21, 2023 | Common Stock | SSaleDisposed | −164 | $21.40F9 | −$3,509.6 | 11,970 | Indirect | |
| Dec 21, 2023 | Common Stock | SSaleDisposed | −163 | $21.40F9 | −$3,488.2 | 11,968 | Indirect | |
| Dec 21, 2023 | Common Stock | SSaleDisposed | −163 | $21.40F9 | −$3,488.2 | 11,967 | Indirect | |
| Dec 21, 2023 | Common Stock | SSaleDisposed | −163 | $21.40F9 | −$3,488.2 | 11,962 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $20.795 to $21.440, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $20.860 to $21.800, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.